This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2001 Nov 10;358(9293):1565-6.

doi: 10.1016/S0140-6736(01)06666-1.

Continuing controversy over adjuvant therapy of pancreatic cancer

R A Abrams¹, K D Lillemoe, S Piantadosi

Affiliations

PMID: 11716876
DOI: 10.1016/S0140-6736(01)06666-1

Comment

Continuing controversy over adjuvant therapy of pancreatic cancer

R A Abrams et al. Lancet. 2001.

. 2001 Nov 10;358(9293):1565-6.

doi: 10.1016/S0140-6736(01)06666-1.

Authors

R A Abrams¹, K D Lillemoe, S Piantadosi

Affiliation

¹ Department of Oncology, Johns Hopkins Hospital and School of Medicine, Baltimore, MD 21231, USA. abramro@jhmi.edu

PMID: 11716876
DOI: 10.1016/S0140-6736(01)06666-1

No abstract available

PubMed Disclaimer

Comment on

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. Lancet. 2001 Nov 10;358(9293):1576-85. doi: 10.1016/s0140-6736(01)06651-x. Lancet. 2001. PMID: 11716884 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information